Philippe Lucas PhD is a Research Affiliate at the Michigan Psychedelic Center (UMich) and a lifelong cannabis and psychedelic researcher and patient access advocate. Philippe was a founding Board member of the Multidisciplinary Association of Psychedelic Studies Canada and co-founder of the Victoria Association of Psychedelic Studies. He is the Primary Investigator of the Canadian Psychedelic Survey (2022) and co-PI of the Global Psychedelic Survey (2023), and previously coordinated a prospective observational study of ayahuasca as a treatment for trauma and addiction in cooperation with a BC indigenous Band. More recently, Philippe worked as VP, Global Patient Research & Access at Tilray, where he oversaw a comprehensive international clinical and observational cannabis research program.
Philippe has worked with governments around the globe to develop evidence-based drug policies with a focus on harm reduction and safe, legal access, and has received a number of accolades for his patient research and advocacy, including the Americans for Safe Access Researcher of the Year Award 2021, the Cannabis Council of Canada Lifetime Achievement Award, and the Queen Elizabeth II Diamond Jubilee Medal.